
STRO Stock Forecast & Price Target
STRO Analyst Ratings
Bulls say
Sutro Biopharma is poised for significant growth thanks to their strong operational execution and the promising clinical development of their product candidates, particularly STRO-004 which has shown differentiated safety data and potential for commercialization in various tumor types. With a solid balance sheet and increased price target from $28 to $50, Sutro is well-positioned for success in the oncology market and has strong potential for future mergers and acquisitions.
Bears say
Sutro Biopharma is currently developing STRO-004, a single homogeneous ADC directed against tissue factor, for the treatment of solid tumors. Based on recent efficacy and safety data for STRO-004, as well as the regulatory and financial risks involved in drug development, it is likely that the company may face challenges in achieving successful clinical trials and obtaining regulatory approvals, ultimately negatively impacting the company's stock performance. Additionally, Sutro may face significant competition in the cancer therapeutics industry, potentially limiting the success of its products in the market. Based on these factors, this financial analyst has a negative outlook on the stock.
This aggregate rating is based on analysts' research of Sutro Biopharma Inc and is not a guaranteed prediction by Public.com or investment advice.
STRO Analyst Forecast & Price Prediction
Start investing in STRO
Order type
Buy in
Order amount
Est. shares
0 shares